|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 283, Issue 24, 16940-16949, June 13, 2008
Foxa2 Activity Increases Plasma High Density Lipoprotein Levels by Regulating Apolipoprotein M*![]() ![]() ![]() ¶![]() ¶1
From the
Obesity, diabetes, insulin resistance, and hyperinsulinemia are frequently associated with a cluster of closely related lipid abnormalities such as low plasma levels of high density lipoprotein (HDL) and elevated levels of triglyceride, both known to increase the risk of developing atherosclerotic disease. The molecular mechanisms linking obesity, insulin resistance, and hyperinsulinemia to low HDL levels are incompletely understood. Here we demonstrate that insulin, through a Foxa2-mediated mechanism, inhibited the expression of apolipoprotein M (apoM), an important determinant of plasma pre-β-HDL and
Received for publication, March 10, 2008 * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence should be addressed: Inst. of Molecular Systems Biology, Swiss Federal Inst. of Technology, ETH Zürich, HPT E73, Wolfgang-Pauli Str. 16, 8093 Zürich, Switzerland. Tel.: 41-44-633-4560; Fax: 41-44-633-1051; E-mail: stoffel{at}imsb.biol.ethz.ch.
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||